ZA200708600B - Novel liposome compositions - Google Patents

Novel liposome compositions

Info

Publication number
ZA200708600B
ZA200708600B ZA200708600A ZA200708600A ZA200708600B ZA 200708600 B ZA200708600 B ZA 200708600B ZA 200708600 A ZA200708600 A ZA 200708600A ZA 200708600 A ZA200708600 A ZA 200708600A ZA 200708600 B ZA200708600 B ZA 200708600B
Authority
ZA
South Africa
Prior art keywords
liposome compositions
novel liposome
novel
compositions
liposome
Prior art date
Application number
ZA200708600A
Other languages
English (en)
Inventor
Okada Kazuski
Ibuki Tadayaki
Kim Donghyun
Fujisawa Tadashi
Original Assignee
Mebiopharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mebiopharm Co Ltd filed Critical Mebiopharm Co Ltd
Publication of ZA200708600B publication Critical patent/ZA200708600B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200708600A 2005-03-10 2006-03-08 Novel liposome compositions ZA200708600B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005067469A JP2006248978A (ja) 2005-03-10 2005-03-10 新規なリポソーム製剤

Publications (1)

Publication Number Publication Date
ZA200708600B true ZA200708600B (en) 2009-01-28

Family

ID=36992280

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708600A ZA200708600B (en) 2005-03-10 2006-03-08 Novel liposome compositions

Country Status (21)

Country Link
US (3) US7829113B2 (https=)
EP (1) EP1863448B1 (https=)
JP (2) JP2006248978A (https=)
KR (1) KR101352490B1 (https=)
CN (1) CN101170995B (https=)
AU (1) AU2006223329B2 (https=)
BR (1) BRPI0608297A2 (https=)
CA (1) CA2600446A1 (https=)
CY (1) CY1116075T1 (https=)
DK (1) DK1863448T3 (https=)
ES (1) ES2529453T3 (https=)
HU (1) HUE024290T2 (https=)
MX (1) MX2007010996A (https=)
NO (1) NO20075136L (https=)
NZ (1) NZ561569A (https=)
PL (1) PL1863448T3 (https=)
PT (1) PT1863448E (https=)
RU (1) RU2454229C2 (https=)
SI (1) SI1863448T1 (https=)
WO (1) WO2006099169A2 (https=)
ZA (1) ZA200708600B (https=)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
EP2187869B1 (en) * 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
JP5854559B2 (ja) * 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CA2781527C (en) * 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
SG10202010355PA (en) * 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
ES2987670T3 (es) 2010-03-19 2024-11-15 1Globe Biomedical Co Ltd Métodos novedosos para actuar sobre células madre cancerosas
EP2558108A1 (en) * 2010-04-12 2013-02-20 Ramot at Tel-Aviv University Ltd Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders
AU2011325966B2 (en) 2010-11-12 2016-09-29 Oncour Pharma, Inc. Modified immune-modulating particles
WO2012153616A1 (ja) * 2011-05-10 2012-11-15 国立大学法人北海道大学 標的細胞移行能を有する脂質膜構造体、その製造方法および標的細胞において効果を示す物質のスクリーニング方法
JP5983608B2 (ja) * 2011-07-15 2016-09-06 コニカミノルタ株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
JP2015509085A (ja) * 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
EP2883542B1 (en) 2012-08-10 2019-05-01 Taiho Pharmaceutical Co., Ltd. Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
US10188728B2 (en) 2012-12-12 2019-01-29 Temple University—Of the Commonwealth System of Higher Education Compositions and methods for treatment of cancer
CN103083239B (zh) * 2012-12-26 2015-11-25 中国人民解放军第四军医大学 一种蟾毒灵脂质体及其制备方法和应用
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
US10039716B2 (en) * 2013-03-13 2018-08-07 Mallinckrodt Llc Liposomal cisplatin compositions for cancer therapy
CA2903234C (en) * 2013-03-13 2018-08-28 Mallinckrodt Llc Liposome oxaliplatin compositions for cancer therapy
EP3494966B1 (en) 2013-03-13 2024-04-03 onCOUR Pharma, Inc. Immune-modifying particles for the treatment of inflammation
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
KR20160042079A (ko) 2013-08-13 2016-04-18 노쓰웨스턴유니버시티 펩티드-접합된 입자
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2015183357A2 (en) * 2014-02-21 2015-12-03 The Curators Of The University Of Missouri Compositions and methods for boron neutron capture therapy
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
EP3212165B1 (en) 2014-10-30 2024-02-28 President and Fellows of Harvard College Delivery of negatively charged proteins using cationic lipids
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
CN107709286B (zh) 2015-06-24 2021-02-19 日本化药株式会社 新型铂(ⅳ)络合物
JP7042739B2 (ja) 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
TW202400181A (zh) 2015-08-21 2024-01-01 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
WO2017047497A1 (ja) 2015-09-14 2017-03-23 日本化薬株式会社 ６配位白金錯体の高分子結合体
EP4647126A3 (en) 2015-10-16 2026-02-11 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
WO2017087685A1 (en) * 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
JP6831796B2 (ja) 2015-12-22 2021-02-17 日本化薬株式会社 スルホキシド誘導体配位白金（ｉｉ）錯体の高分子結合体
CN109678910B (zh) * 2016-01-25 2021-09-07 沈阳药科大学 一种化合物及其应用以及一种铂类配合物及其脂质体
EP3426781B1 (en) 2016-03-07 2024-06-26 The United States of America, as represented by The Secretary, Department of Health and Human Services Micrornas and methods of their use
EP3444004B1 (en) * 2016-04-15 2020-12-02 FUJIFILM Corporation Microneedle array
WO2017217517A1 (ja) * 2016-06-17 2017-12-21 国立大学法人大阪大学 腫瘍内静脈形成促進剤
JP7019201B2 (ja) * 2016-08-02 2022-02-15 キュリアールエックス インコーポレーテッド リポソームの調製方法
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018031968A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
CN121177507A (zh) 2016-08-12 2025-12-23 L.E.A.F.控股集团公司 α和γ-D聚谷氨酸化抗叶酸剂及其用途
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
CA3058782A1 (en) 2017-04-03 2018-10-11 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
WO2018209342A1 (en) * 2017-05-12 2018-11-15 Curinanorx, Llc Methods for the preparation of liposomes comprising drugs
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3749314A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATE METHOTREXATE AND ITS USES
US12310966B2 (en) 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
CN111867593A (zh) 2018-02-07 2020-10-30 L.E.A.F.控股集团公司 α聚谷氨酸化抗叶酸剂及其用途
JP7491572B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
EP3749319A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
CA3090389A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
WO2019157121A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
WO2019157145A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
WO2019160734A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
US12350271B2 (en) 2018-02-14 2025-07-08 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
WO2019160735A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
CA3090753A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
JP7462950B2 (ja) 2018-02-14 2024-04-08 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化メトトレキセートおよびその使用
CN112437674A (zh) * 2018-04-11 2021-03-02 新墨西哥科技大学研究园公司 用于药物递送的脂质前药
CN108524450A (zh) * 2018-04-16 2018-09-14 温州医科大学 基于磁性热敏阳离子脂质体的奥沙利铂和mdc1-as共传递药物载体的制备及应用
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
IL281470B2 (en) 2018-09-28 2025-08-01 Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
HRP20240586T1 (hr) 2018-10-09 2024-07-19 The University Of British Columbia Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN111721841B (zh) * 2019-03-19 2022-07-12 海南长安国际制药有限公司 与洛铂有关物质的检测
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN110292563B (zh) * 2019-06-12 2021-07-16 兰州大学 基于叶酸热敏脂质体的阴离子载体诱导癌细胞凋亡的方法
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US20230112563A1 (en) * 2020-03-04 2023-04-13 Siemens Healthcare Diagnostics Inc. Compositions and methods of using modified liposomes
KR20230023612A (ko) 2020-04-02 2023-02-17 마이레큘, 인크. 조작된 올리고뉴클레오티드를 사용한 표적화된 억제
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
CN112129871B (zh) * 2020-09-04 2021-06-15 斯微(上海)生物科技有限公司 复合磷脂脂质体中dope和m5两种磷脂含量的检测方法
CN112870164B (zh) * 2021-01-25 2021-12-17 山东大学 一种双靶向载药脂质体及其制备方法和应用
WO2023196851A1 (en) 2022-04-06 2023-10-12 President And Fellows Of Harvard College Reversing aging of the central nervous system
KR20250146635A (ko) 2024-04-01 2025-10-13 고려대학교 산학협력단 리포좀 폴록사머 복합체를 포함하는 통증 질환 치료 조성물

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GR75598B (https=) 1980-04-29 1984-08-01 Sanofi Sa
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US4925661A (en) * 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US4789633A (en) 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
WO1986004232A1 (en) * 1985-01-18 1986-07-31 Cooper-Lipotech, Inc. Liposome composition and method
US5026651A (en) * 1985-04-25 1991-06-25 Board Of Regents, The University Of Texas System Methods and compositions for the production of human transferrin
PH26160A (en) * 1985-08-19 1992-03-18 Univ Texas Pharmaceutical compositions consisting of acylated phospholipids
US4983397A (en) * 1985-08-19 1991-01-08 Board Of Regents, University Of Texas System Pharmaceutical compositions consisting of acylated phospholipids
US5384127A (en) * 1985-10-18 1995-01-24 Board Of Regents, The University Of Texas System Stable liposomal formulations of lipophilic platinum compounds
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
FR2631826B1 (fr) * 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US5474772A (en) * 1989-08-02 1995-12-12 Cobe Laboratories, Inc. Method of treatment with medical agents
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2093665A1 (en) * 1990-10-09 1992-04-10 Sean M. Sullivan Phospholipid analogue vesicle
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US6509032B1 (en) 1991-08-28 2003-01-21 Mcmaster University Cationic amphiphiles
US5292524A (en) * 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
JPH0776230B2 (ja) * 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JP2673331B2 (ja) * 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
JPH06287021A (ja) * 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
US20030190638A1 (en) 1992-05-13 2003-10-09 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US20030100489A1 (en) * 1992-10-16 2003-05-29 Beach David H. Cell-cycle regulatory proteins, and uses related thereto
WO1994026254A1 (en) 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
JP3025602B2 (ja) * 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
KR100372006B1 (ko) * 1993-10-06 2003-07-18 암겐 인코포레이티드 안정한단백질:인지질조성물및그의제조방법
CA2179014C (en) * 1993-12-17 2003-07-29 Spinal Cord Society Method for inducing dna synthesis in neurons
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
DE69527194T2 (de) 1994-03-28 2003-02-06 Daiichi Pharmaceutical Co., Ltd. Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel
EP0773921B1 (en) 1994-07-29 1999-12-01 Abbott Laboratories Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane
AU2989695A (en) * 1994-08-08 2000-03-07 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation
ES2153053T3 (es) * 1994-10-14 2001-02-16 Liposome Co Inc Liposomas de eter-lipido y su uso terapeutico.
ES2206478T3 (es) 1994-11-11 2004-05-16 Debiopharm S.A. Composiciones carcinostaticas que contienen cis-oxaliplatino y otra u otras sustancias carcinostaticas compatibles.
US5786214A (en) * 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
TW319763B (https=) 1995-02-01 1997-11-11 Epix Medical Inc
US5780052A (en) * 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
US5834012A (en) 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US20020022264A1 (en) 1995-05-26 2002-02-21 Sullivan Sean M. Delivery vehicles comprising stable lipid/nucleic acid complexes
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
JPH09278785A (ja) 1996-04-10 1997-10-28 Tanaka Kikinzoku Kogyo Kk 白金化合物の製造方法
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6428977B1 (en) 1995-12-20 2002-08-06 Curis, Inc. Signalin family of TGFβ signal transduction proteins, and uses related thereto
JP3735921B2 (ja) * 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
AU2112697A (en) * 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
EP0897389B1 (fr) 1996-03-11 2002-07-03 Yoshinori Kidani Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant
EP0914094A4 (en) * 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
JP3919227B2 (ja) * 1996-05-02 2007-05-23 テルモ株式会社 アミジン誘導体及びそれを構成成分とする薬物担体
ATE252372T1 (de) 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
HUP0000522A3 (en) 1996-10-15 2000-10-30 Transave Inc Monmouth Junction N-acyl phoshpatidylethanolamine-mediated liposomal drug delivery
EP0964690B1 (en) * 1996-10-15 2003-07-09 The Liposome Company, Inc. Peptide-lipid conjugates, liposomes and liposomal drug delivery
WO1998027209A1 (en) 1996-12-18 1998-06-25 Emory University Polycationic oligomers
EP1014990B1 (en) * 1997-03-07 2006-09-06 Sanofi-Aventis U.S. LLC Antitumor combination of 3-amino-1,2,4-benzotriazine 1,4-dioxide/paclitaxel/platinum
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
JPH10253632A (ja) * 1997-03-10 1998-09-25 Nissui Pharm Co Ltd 分析方法、キット及び装置
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6524613B1 (en) * 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
US6272370B1 (en) * 1998-08-07 2001-08-07 The Regents Of University Of Minnesota MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
WO1998059035A2 (en) 1997-06-25 1998-12-30 The Goverment Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health Serum-free cell growth medium
AU742407B2 (en) * 1997-07-15 2002-01-03 Regents Of The University Of California, The Isolated DNA encoding human calcium activated potassium channel
DE69838584T2 (de) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
AU742438C (en) * 1997-10-02 2003-05-22 Lantheus Medical Imaging, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6320017B1 (en) * 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
US6573101B1 (en) * 1998-02-12 2003-06-03 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6245427B1 (en) * 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
US6866857B1 (en) * 1998-10-14 2005-03-15 Debiopharm S.A. Oxalipatinum preparation packaging
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7312318B2 (en) * 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
AU5136100A (en) 1999-05-17 2000-12-05 Avi Biopharma, Inc. Combined approach to treatment of cancer with hcg vaccines
JP2001002592A (ja) 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
US6280054B1 (en) * 1999-07-02 2001-08-28 Zight Corporation Image generator having an improved illumination system
US6242188B1 (en) * 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
EP1204241A1 (en) * 1999-08-09 2002-05-08 Fujitsu Limited Package control device and method
RU2252022C2 (ru) 1999-08-30 2005-05-20 Дебиофарм С.А. Стабильный фармацевтический препарат оксалиплатины для парентерального введения
MXPA02006121A (es) 1999-12-30 2004-08-23 Judith K Gwathemy Sistema de suministro de formador de quelatos de hierro.
CA2395636A1 (en) 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
EP1471870B1 (en) * 2000-01-10 2014-08-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US6530944B2 (en) * 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7001735B2 (en) * 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
ES2291295T3 (es) * 2000-03-02 2008-03-01 Mitsubishi Pharma Corporation Construccion con enlace gpib-lipido y su uso.
JP4449147B2 (ja) 2000-03-22 2010-04-14 日油株式会社 ホスファチジルエタノールアミン誘導体の製造方法
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
DE60122304T2 (de) 2000-04-12 2007-08-09 Liplasome Pharma A/S Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
PL366025A1 (pl) * 2000-05-03 2005-01-24 Munich Biotech Ag Kationowe środki diagnostyczne, obrazujące i terapeutyczne, zasocjowane z uaktywnionymi miejscami wnaczyniach
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
US20030072794A1 (en) * 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
ATE415414T1 (de) * 2000-09-11 2008-12-15 Pasteur Institut Mitochondrialen membrane permeabilisierung durch hiv-1 vpr und screeningsverfahren
US20040234588A1 (en) 2000-09-21 2004-11-25 University Of Georgia Research Foundation, Inc. Artificial lipoprotein carrier system for bioactive materials
AU2001291583A1 (en) 2000-10-03 2002-04-15 Debiopharm S.A. Method for preparing microspheres containing a water-soluble substance
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
EP1209469A1 (en) * 2000-11-22 2002-05-29 Vectron Therapeutics AG Production and use of a targeted diagnostic system
CA2430868A1 (en) * 2000-12-12 2002-06-20 Australian Institute Of Marine Science Assay for paralytic shellfish toxin
WO2002047725A2 (fr) 2000-12-12 2002-06-20 Debiopharm S.A. Preparation pharmaceutique d'oxaliplatine pour administration par voie parenterale et procede d'obtention de ladite preparation
US6897196B1 (en) * 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US6703524B2 (en) * 2001-02-20 2004-03-09 Lkt Laboratories, Inc. Organoselenium compounds for cancer chemoprevention
DE20221679U1 (de) 2001-03-02 2006-11-23 Debiopharm S.A. Vorrichtung zur Konditionierung einer Oxaliplatinlösung
FI113840B (fi) 2001-03-26 2004-06-30 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
US20040049022A1 (en) * 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
JP2004535388A (ja) 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
US20030082228A1 (en) * 2001-05-09 2003-05-01 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
US20030108986A1 (en) * 2001-06-21 2003-06-12 Euroscreen, S.A. Compositions and methods comprising G-protein coupled receptors
US20040186172A1 (en) 2001-07-02 2004-09-23 Houssam Ibrahim Oxaliplatin active substance with a very low content of oxalic acid
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
US6793912B2 (en) * 2001-08-20 2004-09-21 Transave Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
WO2003028640A2 (en) * 2001-10-03 2003-04-10 Vanderbilt University In vivo panning for ligands to radiation-induced molecules
WO2003044214A2 (en) 2001-11-20 2003-05-30 Baylor College Of Medicine Methods and compositions in checkpoint signaling
JP4468617B2 (ja) 2001-12-04 2010-05-26 デビオファーム エス．アー． 抗癌剤の併用投与方法及び併用可能な抗癌剤
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
JP4360915B2 (ja) 2002-01-07 2009-11-11 ユーロスクリーン・ソシエテ・アノニム Ｇタンパク質共役受容体ｇｐｒ４３のリガンドおよびその使用
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
AU2003278807A1 (en) * 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
WO2003082907A1 (en) 2002-03-29 2003-10-09 Euroscreen Sa Ligands for g protein coupled receptor gpr7 and uses thereof
CA2391438A1 (en) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
FR2840236B1 (fr) 2002-06-03 2005-02-04 Inst Francais Du Petrole Membrane zeolithique de faible epaisseur, sa preparation et son utilisation en separation
JP3415131B1 (ja) * 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
EP1511518A2 (en) * 2002-06-07 2005-03-09 Immunomedics, Inc. Neutrophil imaging methods in cystic fibrosis
RU2005100777A (ru) * 2002-06-14 2005-08-27 Иммуномедикс, Инк. (Us) Моноклональное антитело рам4 и его применение для диагностики и лечения рака поджелудочной железы
ES2524767T3 (es) * 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
US6790632B2 (en) 2002-06-17 2004-09-14 Stephen Eliot Zweig Membrane receptor reagent and assay
EP1519714B1 (en) * 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
JP5138867B2 (ja) 2002-08-01 2013-02-06 イミューノメディクス、インコーポレイテッド α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
US20040132652A1 (en) * 2002-08-30 2004-07-08 Shire Biochem Inc. Pharmaceutical compositions
WO2004045519A2 (en) 2002-11-14 2004-06-03 Kirk Sperber Induction of apoptosis by hiv-1 infected monocytic cells
CN1711074B (zh) 2002-11-15 2010-10-06 尼普洛株式会社 脂质体
AU2003277641B2 (en) 2003-02-17 2009-09-17 Mebiopharm Co., Ltd. Remedy for cancer
WO2004094613A2 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
US7172751B2 (en) * 2003-06-13 2007-02-06 Immunomedics, Inc. D-amino acid peptides
CA2534639C (en) * 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
JP2005154282A (ja) 2003-11-20 2005-06-16 Mebiopharm Co Ltd ガス封入リポソームの製造法
US7582430B2 (en) * 2004-01-20 2009-09-01 United States Of America As Represented By The Secretary Of The Army Immunoliposome-nucleic acid amplification (ILNAA) assay
US7212869B2 (en) * 2004-02-04 2007-05-01 Medtronic, Inc. Lead retention means
CN1679957B (zh) 2004-03-15 2010-06-09 尼普洛株式会社 含脂质体的癌症治疗用药物组合物
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions

Also Published As

Publication number Publication date
EP1863448A2 (en) 2007-12-12
MX2007010996A (es) 2007-11-07
WO2006099169A2 (en) 2006-09-21
NZ561569A (en) 2011-03-31
US20140363491A1 (en) 2014-12-11
PL1863448T3 (pl) 2015-05-29
US20110081404A1 (en) 2011-04-07
ES2529453T3 (es) 2015-02-20
DK1863448T3 (en) 2015-02-16
AU2006223329A1 (en) 2006-09-21
JP5438317B2 (ja) 2014-03-12
KR101352490B1 (ko) 2014-02-04
BRPI0608297A2 (pt) 2009-12-08
JP2008538105A (ja) 2008-10-09
EP1863448B1 (en) 2014-11-26
JP2006248978A (ja) 2006-09-21
WO2006099169A3 (en) 2007-02-22
CY1116075T1 (el) 2017-02-08
NO20075136L (no) 2007-12-07
CN101170995A (zh) 2008-04-30
PT1863448E (pt) 2015-02-10
HUE024290T2 (en) 2016-01-28
CA2600446A1 (en) 2006-09-21
RU2454229C2 (ru) 2012-06-27
HK1111625A1 (en) 2008-08-15
CN101170995B (zh) 2013-01-16
RU2007137492A (ru) 2009-04-20
SI1863448T1 (sl) 2015-03-31
US7829113B2 (en) 2010-11-09
KR20080002819A (ko) 2008-01-04
AU2006223329B2 (en) 2011-11-17
US20060222696A1 (en) 2006-10-05
US8758810B2 (en) 2014-06-24

Similar Documents

Publication Publication Date Title
ZA200708600B (en) Novel liposome compositions
IL229521A0 (en) A new preparation
IL185901A0 (en) Novel composition
IL191572A0 (en) Pestcidal compositions
IL186721A0 (en) Bioenhanced compositions
GB0503337D0 (en) Compositions
IL186093A0 (en) Lignan-containing compositions
GB0526283D0 (en) Compositions
GB0501365D0 (en) Compositions
GB0519164D0 (en) Composition
GB0524128D0 (en) Compositions
GB0506044D0 (en) Composition
GB0507167D0 (en) Composition
EP1847249A4 (en) hair dye
GB0502479D0 (en) Novel compositions
GB0502475D0 (en) Novel compositions
ZA200709913B (en) Bioenhanced compositions
EP1947129A4 (en) PHOTORADIC AND PHOTOCYSTIC CURING COMPOSITION
GB0525321D0 (en) Novel compositions
GB0505760D0 (en) Novel composition
GB0526282D0 (en) Compositions
GB0524803D0 (en) Novel compositions
GB0513367D0 (en) Novel composition
GB0425445D0 (en) Novel compositions
GB0501364D0 (en) Compositions